A first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid leukaemia (CML) in a head-to-head trial, setting up regulatory filings.

The FDA has granted accelerated approval to asciminib as a first-line treatment for adults newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia, a rare type of blood cancer.